Alberto Carturan, MD

Home » Alberto Carturan, MD Researcher Spotlight: Alberto Carturan, MD UNIVERSITY OF PENNSYLVANIA Jaime Peykoff Follicular Lymphoma Fellow Chimeric antigen receptor (CAR) T-cell therapies represent a groundbreaking advancement in the treatment of lymphoma. While CAR T-cell therapies have produced remarkable results for many patients, these agents also carry a risk for potentially severe treatment complications, some of which...

Gonzalo Blanco Ares, PhD

Home » Gonzalo Blanco Ares, PhD Researcher Spotlight: Gonzalo Blanco Ares, PhD THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH Bruce D. Cheson, MD Fellow Care of patients with chronic lymphocytic leukemia (CLL) is complicated by the immunodeficiency that is associated with the disease, which can lead to higher mortality rates due to not only CLL but also other cancers...

Ruth Alonso-Alonso, PhD

Home » Ruth Alonso-Alonso, PhD Researcher Spotlight: Ruth Alonso-Alonso, PhD THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK Oliver W. Press, MD, PhD Memorial Fellow Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of peripheral T-cell lymphoma. Therapeutic options for AITL are limited given patients’ poor responses to conventional chemotherapy, resulting in poor outcomes and...

Yucai Wang, MD

Home » Yucai Wang, MD Researcher Spotlight: Yucai Wang, MD MAYO CLINIC ROCHESTER Dr. Wang’s interest in cancer research began during his time in medical school at Nanjing University in China. He had lost two close family members to lymphoma and was drawn to pursue a doctoral degree in cancer biology from the University of Texas MD...

Timothy Vorhees, MD

Home » Timothy Vorhees, MD Researcher Spotlight: Timothy Vorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Post-transplant lymphoproliferative disorders (PTLDs) are aggressive forms of lymphoma that develop after a solid organ transplant, often due to reactivation of the Epstein-Barr virus (EBV) following the use of immunosuppressants. Treatment options for patients with PTLD are limited, but Dr....